Moreover, preclinical and clinical data suggest that PLK1 inhibition is effective in KRAS-mutant colorectal cancer (32, 70), providing a rationale for more investigation on the combination efficacy with KRASG12C inhibition. Here, PLK1 is linked to colorectal cancer.